[Clinical and pharmacokinetic evaluation of cefotiam in neonates and young infants].
Seven neonates and young infants were treated with cefotiam (CTM) in doses ranging from 8-25.6 mg/kg every 6 to 24 hours for 1 to 14 days, and the clinical efficacy and side effects were evaluated. Among 5 infants with bacterial infections including bacteremia, perianal abscess, pneumonia, urinary tract infection and probable sepsis and meningitis, clinical responses were excellent in 1 and good in 4 patients. In the 7 patients, no side effect attributable to CTM was observed. Serum concentrations of CTM were measured in 5 patients administered with 10 to 20 mg/kg of CTM by bolus intravenous injection. Peak serum concentrations of 21.9 to 38.0 micrograms/ml were noted in samples taken at 15 minutes after injection. Serum half-lives of the drug were 2.35 hours in 2 day-old neonate, 0.72 to 0.85 hours in 3 infants of 25 to 37 days, and 8.46 hours in an 18 day-old neonate with renal insufficiency.
Fujita
K
K
Sakata
H
H
Tanaka
M
M
Kaeriyama
M
M
Yoshioka
H
H
Takimoto
M
M
Takahashi
Y
Y
D001424:Bacterial Infections / Q000188:drug therapy* / Q000378:metabolism; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D015310:Cefotiam; D005260:Female; D006207:Half-Life; D006801:Humans; D007223:Infant; D007231:Infant, Newborn / Q000378:metabolism*; D007275:Injections, Intravenous; D007700:Kinetics; D008297:Male; D008581:Meningitis / Q000188:drug therapy / Q000378:metabolism; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000378:metabolism
D015310:Cefotiam; D002439:Cefotaxime